Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

2(33.3%)

N/A

2(33.3%)

Phase 3

2(33.3%)

6Total

Phase 2(2)

N/A(2)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06423924Not Yet Recruiting

Second Primary Cancer and Early-onset Colorectal Cancer

Role: lead

NCT05879172Not ApplicableCompleted

Electric Tubular Anastomosis in Rectal Cancer

Role: lead

NCT05359406Phase 2Unknown

A Combination Therapy Including Anti-PD-1 Immunotherapy in Rectal Cancer With Refractory Distal Metastasis

Role: lead

NCT04759820Phase 2Unknown

Carbon Nanoparticles vs Indocyanine Green

Role: lead

NCT03415763Phase 3Unknown

Adjuvant Chemotherapy in Patients With Clinical Stage III Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy

Role: lead

NCT03314896Not ApplicableUnknown

Laparoscopic Surgery for T4 Tumor of the Colon Cancer (LST4C Trial)

Role: lead

NCT02852915Phase 3Unknown

Laparoscopic Surgery for T4 Tumor of the Colon Cancer

Role: lead

All 7 trials loaded